| RVA Receipt of Interim Funding Commitment and Leadership Changes |
| 25/03/19 | PRICE SENSITIVE | | Share |
|
| RVA S&P DJI Announces March 2019 Quarterly Rebalance |
| 08/03/19 | PRICE SENSITIVE | | Share |
|
| RVA Response to ASX Appendix 4C Query Letter |
| 22/02/19 | PRICE SENSITIVE | | Share |
|
| RVA Voluntary Suspension |
| 20/02/19 | PRICE SENSITIVE | | Share |
|
| RVA Trading Halt |
| 18/02/19 | PRICE SENSITIVE | | Share |
|
| RVA REVA Announces Reduction in Force |
| 05/02/19 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 31/01/19 | PRICE SENSITIVE | | Share |
|
| RVA REVA expands Geographic Footprint to Seven New Countries |
| 07/01/19 | PRICE SENSITIVE | | Share |
|
| RVA REVA Medical to Present at Canaccord Genuity Forum |
| 15/11/18 | PRICE SENSITIVE | | Share |
|
| RVA Q3 2018 Quarterly Report on Form 10-Q |
| 06/11/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Medical Reports Third Quarter 2018 Financial Results |
| 06/11/18 | PRICE SENSITIVE | | Share |
|
| RVA Commercial Launch of Fantom Encore Bioresorbable Scaffold |
| 01/11/18 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 30/10/18 | PRICE SENSITIVE | | Share |
|
| RVA New Data to be Presented at the TCT 2018 Conference |
| 16/08/18 | PRICE SENSITIVE | | Share |
|
| RVA Half Yearly Report and Accounts (Appendix 4D) |
| 08/08/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Medical Reports Second Quarter 2018 Financial Results |
| 07/08/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Enters into Amendment to License Agreement with Rutgers |
| 06/08/18 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 30/07/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Enters Peripheral Artery Disease Space with MOTIV |
| 26/07/18 | PRICE SENSITIVE | 53.21KB | Share |
|
| RVA REVA Expands Commercial Access to Fantom in Italy |
| 16/07/18 | PRICE SENSITIVE | 53.95KB | Share |
|
| RVA CE Mark Approval of the Full Fantom Encore Product Line |
| 19/06/18 | PRICE SENSITIVE | 53.05KB | Share |
|
| RVA REVA Announces Positive 24-Month Clinical Results |
| 24/05/18 | PRICE SENSITIVE | 60.9KB | Share |
|
| RVA REVA Symposium Showcases Clinical Data |
| 24/05/18 | PRICE SENSITIVE | 5.43MB | Share |
|
| RVA REVA Announces First Implant of Fantom in Turkey |
| 16/05/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Medical Reports First Quarter 2018 Financial Results |
| 09/05/18 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 30/04/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Initiates Commercial Distribution Partnership in Turkey |
| 03/04/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Announces First Implant of Fantom Encore in Switzerland |
| 28/03/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Reports 2017 Financial Results |
| 08/03/18 | PRICE SENSITIVE | | Share |
|
| RVA Preliminary Final Report |
| 28/02/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Announces CE Mark and First Implant of Fantom Encore |
| 26/02/18 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - Quarterly |
| 01/02/18 | PRICE SENSITIVE | | Share |
|
| RVA First Implant of the Fantom Bioresorbable Scaffold in Italy |
| 25/01/18 | PRICE SENSITIVE | | Share |
|
| RVA REVA Medical reports Third Quarter 2017 Financial Results |
| 08/11/17 | PRICE SENSITIVE | | Share |
|
| RVA New Fantom Data Demonstrates Safety at 2 Years |
| 01/11/17 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 31/10/17 | PRICE SENSITIVE | | Share |
|
| RVA Launch of Fantom in Switzerland |
| 16/10/17 | PRICE SENSITIVE | | Share |
|
| RVA Half Yearly Report and Accounts (Appendix 4D) |
| 10/08/17 | PRICE SENSITIVE | | Share |
|
| RVA Boston Scientific Distribution Option Lapses |
| 04/08/17 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 31/07/17 | PRICE SENSITIVE | | Share |
|
| RVA First Commercial Customer |
| 28/06/17 | PRICE SENSITIVE | | Share |
|
| RVA REVA Symposium Showcases Clinical Data |
| 18/05/17 | PRICE SENSITIVE | | Share |
|
| RVA REVA Announces Positive 12-Month Clinical Results |
| 17/05/17 | PRICE SENSITIVE | | Share |
|
| RVA Quarterly Report on Form 10-Q |
| 10/05/17 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 28/04/17 | PRICE SENSITIVE | | Share |
|
| RVA Enrollment Initiated in Expanded FANTOM II Trial |
| 26/04/17 | PRICE SENSITIVE | | Share |
|
| RVA Prospectus for Offering of Convertible Notes and Options |
| 24/04/17 | PRICE SENSITIVE | | Share |
|
| RVA Convertible Note Financing Arranged |
| 24/04/17 | PRICE SENSITIVE | | Share |
|
| RVA REVA Receives CE Mark for Fantom |
| 04/04/17 | PRICE SENSITIVE | | Share |
|
| RVA FANTOM II Trial to be Expanded to More Complex Cases |
| 24/03/17 | PRICE SENSITIVE | | Share |
|
| RVA Preliminary Final Report and Annual Report on Form 10-K |
| 28/02/17 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 31/01/17 | PRICE SENSITIVE | | Share |
|
| RVA Amendment No. 1 to Form 10-Q |
| 09/11/16 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly-RVALL.PK |
| 29/07/16 | PRICE SENSITIVE | | Share |
|
| RVA Preliminary Final Report |
| 26/02/16 | PRICE SENSITIVE | | Share |
|
| RVA FANTOM II Target Patient Enrollment Achieved |
| 24/02/16 | PRICE SENSITIVE | | Share |
|
| RVA Clinical Progress & Anticipated $11.4 Million Cash Receipt |
| 11/02/16 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 29/01/16 | PRICE SENSITIVE | | Share |
|
| RVA Quarterly Report on Form 10-Q |
| 10/11/15 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 30/10/15 | PRICE SENSITIVE | | Share |
|
| RVA REVA Completes Clinical Enrollment Milestone |
| 01/10/15 | PRICE SENSITIVE | | Share |
|
| RVA Regina Groves Appointed as Chief Executive Officer |
| 21/08/15 | PRICE SENSITIVE | | Share |
|
| RVA Half Yearly Report and Accounts (Appendix 4D) |
| 11/08/15 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 31/07/15 | PRICE SENSITIVE | | Share |
|
| RVA Initial Clinical Results for Fantom Scaffold |
| 22/05/15 | PRICE SENSITIVE | | Share |
|
| RVA FANTOM II Clinical Trial Expanded to Australia |
| 15/05/15 | PRICE SENSITIVE | | Share |
|
| RVA REVA Undertakes Search for Chief Executive Officer |
| 14/05/15 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 30/04/15 | PRICE SENSITIVE | | Share |
|
| RVA Fantom II Clinical Trial Expanded to Europe |
| 23/04/15 | PRICE SENSITIVE | | Share |
|
| RVA Initiation of FANTOM II Clinical Trial & Live Implant at ACC |
| 16/03/15 | PRICE SENSITIVE | | Share |
|
| RVA Preliminary Final Report |
| 27/02/15 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 30/01/15 | PRICE SENSITIVE | | Share |
|
| RVA REVA Implants First Patients with Fantom Scaffold |
| 04/12/14 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 31/10/14 | PRICE SENSITIVE | | Share |
|
| RVA Prospectus for Offering of Convertible Notes and Options |
| 24/10/14 | PRICE SENSITIVE | | Share |
|
| RVA Goldman Sachs and Senrigan to Provide Financing |
| 26/09/14 | PRICE SENSITIVE | | Share |
|
| RVA Half Yearly Report and Accounts (Appendix 4D) |
| 08/08/14 | PRICE SENSITIVE | | Share |
|
| RVA Appendix 4C - quarterly |
| 31/07/14 | PRICE SENSITIVE | | Share |
|
| RVAAppendix 4C - quarterly |
| 30/04/14 | PRICE SENSITIVE | | Share |
|
| RVAREVA to Focus on FANTOM Scaffold |
| 27/03/14 | PRICE SENSITIVE | | Share |
|
| RVAPreliminary Final Report |
| 27/02/14 | PRICE SENSITIVE | | Share |
|
| RVAAppendix 4C - quarterly |
| 31/01/14 | PRICE SENSITIVE | | Share |
|
| RVAAppendix 4C - quarterly |
| 31/10/13 | PRICE SENSITIVE | | Share |
|
| RVAImplant & Pilot Trial Update Presentation at TCT Conference |
| 30/10/13 | PRICE SENSITIVE | | Share |
|
| RVAHalf Yearly Report and Accounts (Appendix 4D) |
| 09/08/13 | PRICE SENSITIVE | | Share |
|
| RVAAppendix 4C - quarterly |
| 31/07/13 | PRICE SENSITIVE | | Share |
|
| RVAClinical Trial Expanded to Australia and New Zealand |
| 27/06/13 | PRICE SENSITIVE | | Share |
|
| RVA12-month Data from RESTORE Trial at EuroPCR |
| 21/05/13 | PRICE SENSITIVE | | Share |
|
| RVAAppendix 4C - quarterly |
| 30/04/13 | PRICE SENSITIVE | | Share |
|
| RVAReZolve2 Clinical Trial Initiation |
| 28/03/13 | PRICE SENSITIVE | | Share |
|
| RVAPreliminary Final Report |
| 28/02/13 | PRICE SENSITIVE | | Share |
|
| RVAAppendix 4C - quarterly |
| 31/01/13 | PRICE SENSITIVE | | Share |
|
| RVAAppendix 4C - quarterly |
| 31/10/12 | PRICE SENSITIVE | | Share |
|
| RVAPresentation at TCT Conference |
| 24/10/12 | PRICE SENSITIVE | | Share |
|
| RVAHalf Yearly Report and Accounts (Appendix 4D) |
| 10/08/12 | PRICE SENSITIVE | | Share |
|
| RVAAppendix 4C - quarterly |
| 31/07/12 | PRICE SENSITIVE | | Share |
|
| RVAInitial Clinical Enrollment of ReZolve is Completed |
| 13/07/12 | PRICE SENSITIVE | | Share |
|
| RVAREVA Medical Announces Interim Clinical Results at EuroPCR |
| 17/05/12 | PRICE SENSITIVE | | Share |
|
| RVAAppendix 4C - quarterly |
| 30/04/12 | PRICE SENSITIVE | | Share |
|
| RVAInstitutions Agree to Acquire REVA Shares |
| 19/03/12 | PRICE SENSITIVE | | Share |
|
